Track 2 – 3:30 PM, Friday, May 24
Confirmed speakers as of May 1, 2013.
Carmen Puliafito was recently reappointed to a second term as dean of the Keck School of Medicine of USC, a position he has held since 2007. He continues to lead the transformation of the Keck School into one of the United States’ preeminent research-intensive medical schools. Puliafito is a renowned ophthalmologist, widely recognized for his innovative advances in treatment, including his co-invention of optical coherence tomography (OCT), which revolutionized laser surgery. In addition to his responsibilities as dean, he is an active clinician and serves as the current editor of Ophthalmic Surgery, Lasers and Imaging.
From 2001 to 2007, Carmen Puliafito served as chair of the department of ophthalmology at the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine. Prior to his work at Bascom Palmer, he served as founding director of the New England Eye Center and chair of the department of ophthalmology at Tufts University (1991 to 2001). A cum laude graduate of Harvard College and a magna cum laude graduate of Harvard Medical School, Puliafito also earned a M.B.A. from the Wharton School of Business at the University of Pennsylvania.
Jae U. Jung (정재웅) is a preeminent expert in the molecular biology of herpes viruses and their gene products as they relate to cell biology, biochemistry and immunology. His research addresses several key biological features of virus-host interactions, with a focus on host immune responses to viruses, mechanisms by which viruses induce tumors, and the ability of viruses to establish life-long infections.
He is a fellow of the American Academy of Microbiology and American Association for the Advancement of Science. In 2012, he received the Ho-Am (호암) Prize in Medicine, one of Korea’s highest honors and often referred to as the Korean equivalent of the Nobel Prize. Prior to his appointment at USC in 2007, he was a Professor of Microbiology and Molecular Genetics at Harvard Medical School and Chair of Tumor Virology Division at the New England Primate Research Center. He was the first Korean-born scientist to receive tenure at Harvard University. He received his Ph.D. from the University of California, Davis in 1989 and his BS and MS from Seoul National University in Korea in 1982 and 1984 respectively.
At USC, Dr. Jung has and will continue to strengthen the basic science efforts and the faculty’s significant contributions in the arena of scientific discovery. He has recruited top-notch investigators, organized multi-investigator program grant award for centers of excellence, and enhanced active core facilities to stimulate the research environment. He continues to integrate programs to bridge gaps between basic science and clinical research and promote multidisciplinary translation research on the most pressing diseases including AIDS, tuberculosis, flu, autoimmune diseases, and cancers.
Andrew P. McMahon, FRS., is the W.M. Keck provost professor, the director of the Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research, and the chairman of the Department of Stem Cell Biology and Regenerative Medicine in the Keck School of Medicine of USC.
McMahon obtained a B.A. in zoology from the University of Oxford (1978) and completed his Ph.D. studies in mammalian genetics in the Medical Research Council’s mammalian development unit at University College London, U.K. (1981).
Andrew McMahon is an elected fellow of the American Association for the Advancement of Science (2000), the American Academy of Arts and Sciences (2003), and the Royal Society, UK (2007); and an elected associate member of the European Molecular Biology Organization (2003). Professor McMahon has also served as an editor of the journals Development and Developmental Biology, on the editorial boards of several other scientific journals, and on numerous scientific advisory groups. His work is published in over 250 referred primary research papers. Professor McMahon has received Javitt’s and Merit Awards from the National Institute of Neurological Disorders and Stroke and the National Institute of Diabetes and Digestive and Kidney Diseases, respectively. Professor McMahon holds over 20 patents principally focused around Hedgehog signaling. He was a scientific co-founder of the biotech company Ontogeny/Curis whose initial work lead to the discovery of small molecule pathway modulators of Hedgehog signaling developed and marketed by Genentech as an approved anti-cancer treatment (Erivedge).
The McMahon group’s research focuses on the regulatory processes that construct, maintain and repair organ systems with a principal focus on the central nervous system, skeleton and kidney.